Incyte’s ZYNYZ Approved by FDA as First-Line Treatment for Advanced Anal Cancer
The FDA approved ZYNYZ (retifanlimab-dlwr), a PD-1 inhibitor developed by Incyte, for the treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). The approval includes two indications, in combination with carboplatin and paclitaxel chemotherapy as a first-line treatment, and as monotherapy for patients whose disease progressed on or who are intolerant to platinum-based therapy. This milestone is based on data from the Phase III POD1UM-303/InterAACT2 and Phase II POD1UM-202 trials, which demonstrated significant improv...
